Rosetta Genomics (FRA:RQ1) Total Assets : €5.52 Mil (As of Jun. 2017)

View and export this data going back to 2014. Start your Free Trial

What is Rosetta Genomics Total Assets?

Rosetta Genomics's Total Assets for the quarter that ended in Jun. 2017 was €5.52 Mil.

Total Assets is connected with ROA %. Rosetta Genomics's annualized ROA % for the quarter that ended in Jun. 2017 was -87.43%. Total Assets is also linked to Revenue through Asset Turnover. Rosetta Genomics's Asset Turnover for the quarter that ended in Jun. 2017 was 0.09.

Rosetta Genomics Total Assets Historical Data

The historical data trend for Rosetta Genomics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rosetta Genomics Total Assets Chart

Rosetta Genomics Annual Data

Trend

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Total Assets

Get a 7-Day Free Trial

24.79

18.89

14.01

20.58

11.34

Rosetta Genomics Quarterly Data
	Dec10	Mar11	Jun11	Dec11	Jun12	Dec12	Jun13	Dec13	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Jun17
Total Assets	Get a 7-Day Free Trial															17.30	14.06	11.25	11.34	5.52

Rosetta Genomics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Rosetta Genomics's Total Assets for the fiscal year that ended in Dec. 2016 is calculated as

Total Assets	=	Total Equity (A: Dec. 2016 )	+	Total Liabilities (A: Dec. 2016 )
	=	4.187	+	7.152
	=	11.34

Rosetta Genomics's Total Assets for the quarter that ended in Jun. 2017 is calculated as

Total Assets	=	Total Equity (Q: Jun. 2017 )	+	Total Liabilities (Q: Jun. 2017 )
	=	0.978	+	4.546
	=	5.52

Rosetta Genomics (FRA:RQ1) Total Assets Explanation

Total Assets is connected with ROA %.

Rosetta Genomics's annualized ROA % for the quarter that ended in Jun. 2017 is

ROA %	=	Net Income (Q: Jun. 2017 )	/	( (Total Assets (Q: Dec. 2016 )	+	Total Assets (Q: Jun. 2017 ))	/ count )
	=	-7.372	/	( (11.339	+	5.524)	/ 2 )
	=	-7.372	/	8.4315
	=	-87.43 %

Note: The Net Income data used here is four times the quarterly (Jun. 2017) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Rosetta Genomics's Asset Turnover for the quarter that ended in Jun. 2017 is

	Asset Turnover
=	Revenue (Q: Jun. 2017 )	/	( (Total Assets (Q: Dec. 2016 )	+	Total Assets (Q: Jun. 2017 ))	/ count )
=	0.774	/	( (11.339	+	5.524)	/ 2 )
=	0.774	/	8.4315
=	0.09

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Rosetta Genomics Total Assets Related Terms

Thank you for viewing the detailed overview of Rosetta Genomics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Rosetta Genomics (FRA:RQ1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Rosetta Genomics Ltd (FRA:RQ1) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

10 Plaut Street, Science Park, Rehovot, ISR, 76706

Website

http://www.rosettagenomics.com

Rosetta Genomics Ltd is an Israel based genomic diagnostics company operating globally. It is focused on research and development on diagnostics and therapeutics in the field of microRNAs. The firm markets and sells four diagnostic tests based on its microRNA technologies namely, RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer, mi-LUNG, mi-KIDNEY which is a microRNA-based kidney tumor classification test for pathology samples and RosettaGx Reveal which is a microRNA-based assay for the diagnosis of indeterminate thyroid fine-needle aspirate samples. Its revenues include Clinical testing revenues and Licensing revenues, of which Clinical testing revenue is maximum. The group generates its revenues mainly from diagnosing patient tissue.

Rosetta Genomics (FRA:RQ1) Headlines

No Headlines